Beyond defining the hypoxia-sensitive HIF-1α-SCFJFK axis, which promotes breast carcinogenesis, we extended these molecular and cell-context specific insights into clinical relevance when targeting HIF-1α is not effective, supporting the hypothesis that JFK is a vulnerable target for the development of innovative therapeutic interventions against breast cancer. This evidence concerns the gene FBXO42 and breast cancer.